In addition, gatekeeper mutations have been more readily identified after progression on approved TKIs in EGFR-mutant or ALK fusion-positive non-small-cell lung cancer (NSCLC) as compared with RET fusion-positive NSCLC (Lin et al. 2020). The gene discussed is ALK; the disease is non-small cell lung carcinoma.